Compare TASK & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TASK | ARVN |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 544.9M | 516.2M |
| IPO Year | 2021 | 2018 |
| Metric | TASK | ARVN |
|---|---|---|
| Price | $5.08 | $8.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 19 |
| Target Price | $14.70 | ★ $15.05 |
| AVG Volume (30 Days) | 617.9K | ★ 741.1K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 58.84 |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $5.95 | N/A |
| Revenue Next Year | $6.46 | N/A |
| P/E Ratio | $19.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.47 | $6.06 |
| 52 Week High | $18.39 | $14.22 |
| Indicator | TASK | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 54.11 |
| Support Level | $4.47 | N/A |
| Resistance Level | $6.62 | $10.18 |
| Average True Range (ATR) | 0.30 | 0.44 |
| MACD | 0.03 | 0.17 |
| Stochastic Oscillator | 46.32 | 82.39 |
TaskUs Inc provides outsourced digital services. Its service offerings include Digital Customer Experience consists of omnichannel customer care services, delivered through digital (non-voice) channels, also including learning experience and sales and customer acquisition services; Trust & Safety consists of monitoring, reviewing and managing user and advertiser-generated content on online platforms to ensure it complies with community guidelines, legal regulations and platform specific policies; and AI Services consists of large language model support and high-quality data labeling services, annotation, context relevance and transcription services performed for the purpose of training and tuning machine learning algorithms, enabling them to develop cutting-edge AI systems.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.